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Non-alcoholic fatty liver disease (NAFLD) is currently evolving as the most common liver disease worldwide. It may progress to
liver cirrhosis and liver cancer and is poised to represent the most common indication for liver transplantation in the near future.
The pathogenesis of NAFLD is multifactorial and not fully understood, but it represents an insulin resistance state characterized
by a cluster of cardiovascular risk factors including obesity, dyslipidemia, hyperglycemia, and hypertension. Importantly, NAFLD
also has evolved as independent risk factor for cardiovascular disease. Unfortunately thus far no established treatment does exist
for NAFLD. The bile acid-activated nuclear farnesoid X receptor (FXR) has been shown to play a role not only in bile acid but
also in lipid and glucose homeostasis. Specific targeting of FXR may be an elegant and very eﬀective way to readjust dysregulated
nuclear receptor-mediated metabolic pathways. This review discusses the body’s complex response to the activation of FXR with
its beneficial actions but also potential undesirable side eﬀects.

1. Introduction
One characteristic of our modern civilization is the easy
and unlimited access to unhealthy and caloric dense food.
A typical American diet furnishes the liver with ∼20 g of fat
each day, equivalent to one-half of the total triglyceride content of the liver. In combination with little need for physical
activity due to technological advances, one consequence of
our sedentary and excessive lifestyle is non-alcoholic fatty
liver disease (NAFLD).
NAFLD is a major health problem aﬀecting up to 60
million Americans and evolving as the most common liver
disease worldwide [1, 2]. This is several-fold higher than
other common chronic liver diseases such as hepatitis C
and alcohol-related liver disease. While the majority of
subjects with NAFLD are obese, the condition can occur in
the absence of obesity or other features of the metabolic
syndrome. In patients with diabetes and morbid obesity the
prevalence of NAFLD has been shown to be as high as 62%
and 96%, respectively [3, 4].
The earliest stage of NAFLD is fatty liver that is defined
as the presence of cytoplasmic triglyceride droplets in more
than 5% of hepatocytes [5]. Although often self-limited,

in 12–40% it can progress to non-alcoholic steatohepatitis
(NASH) [6]. NASH is distinguished from simple fatty liver
by the presence of hepatocyte injury such as hepatocyte
ballooning and apoptosis, an inflammatory infiltrate, and/or
collagen deposition. Over a time period of 10–15 years,
15% of patients with NASH will progress to liver cirrhosis
[7]. Once cirrhosis has developed in the absence of viral
hepatitis, hepatic decompensation occurs at a rate of 4%
annually while the ten-year risk of developing liver cancer
is 10% [7, 8]. Although liver cancer secondary to NASH
typically develops in the setting of cirrhosis, carcinogenesis
can occur in the absence of advanced liver disease. It is
thus not surprising that NAFLD is poised to become the
primary indication for liver transplantations. Like other
causes of chronic liver disease, NASH recurs following liver
transplantation almost universally [9].

2. Basic Pathophysiological Concepts and
Treatment of NAFLD
The pathogenesis of NAFLD is multifactorial and only
partially understood. Fatty liver arises in the setting of
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Figure 1: Hepatic triglyceride (TG) formation, acquisition, and removal. Fatty liver is a result of an imbalance between free fatty acids
(FFAs), and TG input and FFA and TG output. FFA derives from peripheral tissue, endogenous synthesis or diet in form of chylomicrons.
Carbohydrate intake increases glucose and insulin levels thereby promoting lipogenesis through the activation of transcription factors sterol
regulatory element-binding protein 1c (SREBP) and carbohydrate responsive element-binding protein (ChREBP). Reducing the FFA burden
include β-oxidation in mitochondria, storage as TG, or export as very low-density lipoprotein (VLDL).

an imbalance between triglyceride formation/acquisition
and removal (Figure 1). Assembly of triglycerides and lipid
droplet formation requires fatty acids that can derive from
diet, de novo synthesis, or adipose tissue. Dietary fat
packed in chylomicrons is hydrolyzed releasing free fatty
acids of which approximately 20% are delivered to the
liver [8]. Carbohydrate-enriched diets promote de novo
synthesis of free fatty acids via insulin-stimulated activation
of sterol regulatory element-binding protein-1c [10, 11].
In addition, glucose facilitates lipogenesis via activation
of carbohydrate responsive element-binding protein [12].
In the fasting state, a decline of insulin levels stimulates
adipocyte triglyceride hydrolase thereby releasing free fatty
acids that are transported to the liver [13]. In the liver,
free fatty acids can be (i) used for energy and ketone body
production via mitochondrial β-oxidation, (ii) esterified and
stored as triglycerides in lipid droplets, or (iii) packaged
with apolipoprotein B into very low-density lipoproteins
that are secreted into the circulation. As the liver extracts
approximately 20% of free fatty acids from the circulation,
the daily input of triglycerides from diet and fatty acids
from adipocyte tissue is equivalent to the entire triglyceride
content of the liver [14]. Once the capacity of the liver to

store fatty acids in form of triglycerides is overwhelmed,
NASH, diﬀerentiated from a fatty liver by the presence of
increased cell injury, apoptosis, inflammation, and fibrosis,
starts to develop. A detailed review of the steps involved in
the progression of NAFLD to NASH and cirrhosis has been
recently published [15].
Treatment of NAFLD should either prevent disease
progression to liver cirrhosis or reverse already established
NASH, respectively. Despite many advances in our understanding of the pathogenesis of NAFLD, there is currently
no established treatment available. Life-style changes and
exercise to reduce body weight and treatment of concomitant
diabetes and dyslipidemia are accepted first-line therapy but
have not been shown to convincingly reduce the risk of
disease progression [16]. Therefore exploring new avenues
for treatment of this common disease is crucial.

3. The Bile Acid-Activated Nuclear
Farnesoid X Receptor (FXR)
Nuclear receptors are a group of transcription factors that
consist of 48 members in humans. They have a common
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structure consisting of a ligand-independent activation
domain for interaction with cofactors, a central DNA
binding domain, and a unique ligand binding domain
allowing receptor dimerization and coregulator interactions.
Most nuclear receptors function either as homodimers or
as heterodimers with the retinoid X receptor. Binding of
the ligand promotes conformational changes facilitating
the release of corepressors and resulting in conformational
changes of chromatin enabling access of the transcriptional
machinery to the respective promoters. Upon ligand activation, the corepressor complex dissociates and the coactivator
complex is recruited allowing start of transcription. Control
of nuclear transcriptional activity is also thought to occur by
posttranslational modifications [17–19].
In 1995 a protein was discovered that was interacting
with the human retinoic X receptor and named retinoic X
receptor-interacting protein 14 [20]. Because it was activated
by an intermediate of the mevalonate pathway, farnesol, it
was renamed to farnesoid X receptor [21]. Another four
years later, three independent groups [22–24] discovered bile
acids as endogenous ligands for FXR. From an evolutionary
point of view the FXR gene is highly conserved suggesting
that it plays an important role in many species. At the
tissue level, FXR is expressed predominantly in the liver,
intestine, kidney, and adrenal gland. Expression in heart
and adipose tissue is low [25]. The generation of mice with
Fxr gene ablation identified FXR as a master regulator in
bile acid homeostasis [26]. Subsequently novel functions of
FXR have been identified including protecting the intestinal
barrier and modulating the innate immunity [27, 28] and
tumorigenesis [29, 30]. The most important roles of FXR are
likely in regulating metabolic processes.

4. FXR as Key Player in Multiple
Metabolic Processes
For a long time, physiological eﬀects of bile acids have mainly
been attributed to their physicochemical properties [31]. In
the last couple of years it has been evident that bile acids act
like signaling molecules [32] regulating not only their own
homeostasis during the enterohepatic circulation but also
triglyceride, cholesterol, and glucose metabolism.
4.1. Bile Acid Metabolism. A major physiological role of
FXR in bile acid metabolism is to protect hepatocytes
from the deleterious eﬀects of increased bile acid levels by
inhibiting endogenous bile acid synthesis and accelerating
bile acid biotransformation and excretion. In this regard,
FXR-mediated eﬀects occur in a tightly coordinated fashion
at the level of the hepatocyte and enterocyte and have been
reviewed in detail elsewhere [33].
4.2. Triglyceride and Cholesterol Metabolism. It has been
known for years that bile acids can modulate lipid
metabolism in humans. Reducing the transhepatic flux of
bile acids decreases low-density lipoprotein cholesterol and
increases high-density lipoprotein cholesterol and very lowdensity lipoprotein triglyceride levels. Opposite eﬀects are
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observed when the bile acid pool is expanded [34–36].
Studies in mice with Fxr gene ablation or administering FXR
agonists provided key information demonstrating a central
role of FXR in lipid homeostasis.
As illustrated in Figure 2, FXR activation of short
heterodimer partner is required to suppress sterol regulatory element-binding protein 1c expression [37]. As sterol
regulatory element-binding protein 1c is known to regulate
several genes involved in fatty acid and triglyceride formation [11], FXR-mediated repression of sterol regulatory
element-binding protein 1c inhibits triglyceride and fatty
acid synthesis and secretion. Interestingly, recent studies
support the concept that FXR-independent mechanisms may
also contribute [38]. In addition to decreasing lipogenesis,
activation of FXR facilitates the clearance of very low-density
lipoproteins and chylomicrons. This is achieved by increasing
the expression of the very low-density lipoprotein receptor
[39], a protein that enhances lipoprotein lipase-mediated triacylglycerol hydrolysis. Very low-density lipoprotein assembly is controlled by FXR via repressing the expression of
microsomal triglyceride transfer protein and apolipoprotein
B [38]. FXR also activates syndecan-1, a transmembrane
protein that binds remnant particles before their transfer
to receptors [40]. Activation of lipoprotein lipase, a key
enzyme involved in the lipolysis of triglyceride rich lipoproteins, is also FXR-dependent. This involves activation of
apolipoproteins C-II and AIV [41–43] and inhibiting the
expression of apolipoprotein C-III [44] and angiopoetinlike 3 [37], respectively. Another eﬀect of FXR activation is
the induction of peroxisome proliferator-activated receptor α
that promotes fatty acid β-oxidation [45]. Collectively these
findings support the concept that FXR activation decreases
plasma triglyceride levels by suppressing hepatic lipogenesis
and triglyceride secretion and increasing the clearance of
triglyceride-rich lipoproteins from blood. These observations therefore support the concept that FXR activation may
have a beneficial eﬀect in patients with NAFLD by decreasing
hepatic lipogenesis.
Activation of FXR also modulates the reverse cholesterol
transport, a pathway that promotes cholesterol delivery from
the periphery to the liver for biliary disposal and fecal
elimination. In this scenario, the selective uptake of highdensity lipoprotein cholesteryl ester via scavenger receptor
BI [46], intracellular cholesteryl ester hydrolysis facilitated
by neutral cholesteryl ester hydrolase [47], as well as the
canalicular routing of cholesterol by sterol carrier protein 2
[48] for biliary excretion via adenosine triphosphate binding
cassette subfamily G member 5/8 [49] are positively regulated
by FXR [50]. In addition but controversial, FXR appears
to suppress apolipoprotein A-I expression [46, 50, 51],
the primary protein constituent of high-density lipoprotein
defining its size and shape. This may be of particular importance as it could influence the capability of high-density
lipoprotein to remove cholesterol from peripheral cells,
activating the lecithin-cholesterol acyl transferase enzyme
and delivering the resulting cholesteryl ester to the liver.
Another target of FXR is paraoxonase 1, a protein produced
in the liver with phospholipase A2 activity that may be
important for inactivation of proatherogenic lipids produced
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Figure 2: Eﬀect of FXR activation on triglyceride and cholesterol metabolism in the liver. FXR agonists result in a variety of responses
modulating triglyceride (TG) and cholesterol metabolism. Activation of FXR inhibits triglyceride (TG)/fatty acid (FA) synthesis facilitated
by suppressing sterol regulatory element-binding protein 1c (SREBP1c) via activation of short heterodimer partner (SHP). FXR controls
assembly of very low-density lipoprotein (VLDL). FXR may increase the clearance of TG by stimulating lipoprotein lipase (LPL) activity
as well as the hepatic uptake of remnants and low-density lipoprotein by inducing syndecan 1 (SDC1) and the VLDL receptor (VLDLR).
FXR agonists may modulate LDL receptor activity via inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) and activate the reverse
cholesterol transport pathway (RTC). FXR activation also impairs high-density lipoprotein (HDL) formation and suppresses cholesterol
synthesis. apoA1, apoB, apoCII, apoCIII, apoAIV: apolipoprotein A1, B, CII, CIII, AIV; ANGTPL3: angiopoetin like 3; ABCG5/8: adenosine
triphosphate binding cassette subfamily G member 5/8; CEH: cholesterylester hydrolase; HMGCR: 3-hydroxy-3-methylglutaryl coenzyme A
reductase; MTP: microsomal triglyceride transfer protein; PON1: paraoxonase 1; SRBI: scavenger receptor B1; SCP2: sterol carrier protein 2.

by oxidative modification of low-density lipoprotein. FXRmediated repression of paraoxonase 1 involves the induction
of fibroblast growth factor 19, its subsequent binding to the
fibroblast growth factor receptor 4, and activation of the cJun N-terminal kinase pathway [52, 53]. FXR also regulates
the expression of phospholipid transfer protein [54] that is
responsible for the transfer of phospholipids and cholesterol
from low to high-density lipoprotein and suppresses 3hydroxy-3-methyl-glutaryl-CoA reductase likely involving
sterol regulatory element-binding protein 2 [55]. Finally,
FXR represses proprotein convertase subtilisin/kexin 9 [56],
a protein that promotes the intracellular degradation of
the low-density lipoprotein receptor by interfering with
its recycling to the plasma membrane. In summary, these
findings raise concern that activation of FXR may alter
the cholesterol metabolism in a way that increases the
susceptibility to atherosclerosis and thus limit its application
in patients with NAFLD.
4.3. Glucose Homeostasis. In addition to their pleiotropic
eﬀects on lipid metabolism, bile acids also aﬀect glucose
homeostasis. This is supported by an improved glycemic
control in patients with diabetes mellitus response to
cholestyramine [57]. Several studies addressed the role of
bile acids and FXR activation in glucose metabolism, but the
underlying mechanisms are far from being understood. It
appears clear that FXR exerts a role in glucose homeostasis
[58]. In the state of Fxr gene ablation, the failure to

suppress gluconeogenesis and a reduced peripheral glucose
disposal led to glucose intolerance [59–61]. A potential
molecular basis for these observations is the suppression of
hepatic phosphenoyl-pyruvate carboxykinase and glucose 6phosphatase [60, 62]. Reduced plasma levels of free fatty
acids in response to FXR activation (see above) may explain
the increased insulin sensitivity in the liver. Of note, FXR
activation was shown to enhance insulin-stimulated glucose
uptake as well as insulin signaling in adipocytes [61]. It
should be noted that bile acids also modulate glucose
homeostasis in an FXR-independent fashion through cell
signaling pathways [63]. Collectively these findings suggest
that FXR activation might prove useful in the treatment
of hyperglycemia and hyperlipidemia that are present in
patients with NAFLD.
4.4. Hepatic Inflammation and Fibrogenesis. Inflammation
and collagen deposition in the liver are key histopathological
features of NASH. FXR appears to antagonize hepatic
inflammatory processes by antagonizing the nuclear factor
kappa B pathway [64]. Another protective FXR mechanism
involves induction of antimicrobial factors in the intestine
[65]. As FXR is expressed in rodent hepatic stellate cells that
play a critical role in hepatic fibrosis, it is not surprising that
FXR agonists protect against liver fibrosis [66]. This appears
to be mediated by a decreased hepatic expression of various
profibrotic growth factors including transforming growth
factor β1, tissue inhibitor of metalloproteinase 1, α1(I)
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Figure 3: Pro- and antiatherogenic eﬀects of FXR activation. With regard to atherosclerosis, activation of FXR may be associated with
beneficial and potential negative eﬀects. Unless tested in humans, one cannot predict with certainty whether pro- or antiatherogenic eﬀects
are dominant and development of specific FXR modulators may help to avoid some or most of the negative eﬀects. VCAM: vascular cell
adhesion protein. ICAM: intracellular adhesion molecule.

collagen, α smooth muscle actin, matrix metalloproteinase
2 and α2(I) collagen, and microRNA-29a [67–69]. However,
if this mechanism is also operational in humans with a lower
expression level of FXR remains to be determined [70]. These
data suggest that targeting FXR may impact progression from
NAFLD to NASH.

5. FXR and Atherosclerosis
As demonstrated earlier in this article and illustrated in
Figure 3, activation of FXR seems to be associated with both
anti- and proatherogenic properties. In addition to its impact
on dyslipidemia and hyperglycemia, FXR may also directly
act at the levels of the arterial wall. Potential beneficial eﬀects
of FXR activation against atherosclerosis include suppressing
the vasoconstrictive peptide endothelin-1 [71]. Induced
expression of intracellular adhesion molecule 1 and vascular
cell adhesion molecule 1, however, promotes atherosclerosis
by recruiting macrophages to the endothelium [72]. The role
of FXR in the initiation and progression of atherosclerosis
has been studied in mice with Fxr gene ablation that
were backcrossed into atherosclerosis-susceptible strains
with either deletion of the low-density lipoprotein receptor
or apolipoprotein E, respectively [73, 74]. These studies
produced discrepant results whereas more recent experimentations employing an FXR agonist uniformly demonstrated
protection against diet-induced aortic plaque formation
[75, 76]. Translating these findings to humans is not
straightforward as humans carry most cholesterol in LDL
compared to the mouse that lacks cholesteryl ester transfer
protein activity and thus transports most cholesterol in highdensity lipoprotein [77]. In knowledge of these limitations,
it would be most logical to carry out future studies in lowdensity lipoprotein receptor deficient mice that overexpress
human cholesteryl ester transfer protein [78].

6. Summary and Perspective
FXR plays a key role in the transcriptional control of a
myriad of target genes that control metabolic pathways
relevant to NAFLD. By virtue of that role FXR is critically
involved in the development and progression of NAFLD.

Targeting FXR therefore oﬀers exciting new perspectives for
the treatment of NAFLD. However, when interpreting data
obtained in cell culture and rodent models of human disease,
attention needs to be paid to diﬀerences between these
models and humans. One particular challenge in designing
FXR agonists is separating the desired therapeutic eﬀects
from the undesirable side eﬀects. The design of organ- or
gene-specific FXR ligands may enhance the specificity and
reduce side eﬀects of this therapeutic approach. An increased
understanding of the eﬀect of cellular signaling of FXR and
its coregulator proteins has the potential to aid in discovering
novel selective therapeutic modulators and the development
of new and more eﬀective therapeutics. Finally one also needs
to consider that the response to modulation of the FXR
receptor may diﬀer among patient with NAFLD and NASH.
Despite all the concerns raised, it is anticipated that
targeting FXR will result in a more specific and individually
tailored therapy that could revolutionize the management of
NAFLD. Support comes from studies in rats with diabetes
mellitus and fatty liver disease that received the FXR agonist
INT-747 for two months [79]. This intervention decreased
glucose levels and dyslipidemia, protected against body
weight gain, and improved insulin resistance. It is thus very
encouraging that INT-747 also has shown to improve insulin
resistance in patients with diabetes mellitus and NAFLD
[80]. Based on this study with a limited number of patients,
an ongoing large multicenter trial enrolling 280 patients at
eight U.S. centers comprising the NIDDK-sponsored NASH
Clinical Research Network is under way, the results of which
are eagerly awaited.
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